Inversago Pharma Inc.
https://inversago.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inversago Pharma Inc.
Skye Bioscience Looks To Build Appetite For CB1 Obesity Drug
The company will take on Novo Nordisk in reviving the CB1 inhibitor mechanism to develop a more tolerable long-term weight loss drug, after exiting ophthalmology.
Novo Nordisk Bets $256m On Mystery Molecule
The Danish group has licensed an unnamed product with an unknown mechanism.
Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’
Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.
Slow Q3 For Biopharma M&A Boosted By Biogen/Reata
Biogen’s acquisition of Reata lifted the third quarter’s M&A value above $13bn, but data from Evaluate show that acquisition activity cratered in both August and September.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice